New trial aims to tame transplant complications in blood cancer patients

NCT ID NCT04888741

Recruiting now Disease control Sponsor: University of Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests different drug combinations to prevent graft-versus-host disease (GVHD) in 400 blood cancer patients receiving stem cell transplants from unrelated donors. Participants will receive either thymoglobulin or a combination of cyclophosphamide with other immunosuppressants. The goal is to find which approach best prevents GVHD while avoiding relapse, improving overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Thymoglobulin, cyclophosphamide, cyclosporine, sirolimus, mycophenolate mofetil
What this could lead to: If successful, this could identify a safer, more effective way to prevent graft-versus-host disease after stem cell transplants, improving survival and quality of life for blood cancer patients.
What could go wrong: This is a phase II trial, so results are preliminary. The drugs have known side effects like infection risk and organ damage, and the best regimen may still not prevent GVHD in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia B-cell chronic lymphocytic leukemia chronic myelogenous leukemia, BCR-ABL1 positive chronic myelomonocytic leukemia Hodgkins lymphoma Leukemia, Myelogenous, Chronic, BCR-ABL Positive myelodysplastic syndrome Myelodysplastic Syndromes myelofibrosis non-Hodgkin lymphoma plasma cell myeloma Precursor Cell Lymphoblastic Leukemia-Lymphoma primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE MYELOID LEUKEMIA CHRONIC MYELOGENOUS LEUKEMIA CHRONIC MYELOMONOCYTIC LEUKEMIA HODGKIN LYMPHOMA MULTIPLE MYELOMA MYELODYSPLASTIC SYNDROMES MYELOFIBROSIS NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Addenbrookes Hospital
RECRUITING

Cambridge, CB2 0QQ, United Kingdom
Bristol Haematology and Oncology Centre
RECRUITING

Bristol, BS2 8ED, United Kingdom
Churchill Hospital
RECRUITING

Oxford, OX3 7LE, United Kingdom
Derriford Hospital
RECRUITING

Plymouth, PL6 8DH, United Kingdom
Freeman Hospital
RECRUITING

Newcastle upon Tyne, NE7 7DN, United Kingdom
Hammersmith Hospital
RECRUITING

London, W12 0HS, United Kingdom
King's College Hospital
RECRUITING

London, SE5 9RS, United Kingdom
Manchester Royal Infirmary
RECRUITING

Manchester, M13 9WL, United Kingdom
Nottingham City Hospital
RECRUITING

Nottingham, NG5 1PB, United Kingdom
Queen Elizabeth Hospital
RECRUITING

Birmingham, B15 2GW, United Kingdom
Queen Elizabeth Hospital Glasgow
RECRUITING

Glasgow, G51 4TF, United Kingdom
Royal Hallamshire Hospital
RECRUITING

Sheffield, S102JF, United Kingdom
St Jame's University Hospital
RECRUITING

Leeds, LS9 7TF, United Kingdom
The Christie
RECRUITING

Manchester, M20 3QH, United Kingdom
The Royal Marsden Hospital
RECRUITING

Sutton, SM2 5PT, United Kingdom
University College London Hospital
RECRUITING

London, NW1 2BU, United Kingdom
University Hospital of Wales
RECRUITING

Cardiff, Wales, CF14 4XW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.